Motor neurone disease - riluzole (TA20)
Fast, easy summary view of NICE guidance on 'motor neurone disease'
NICE has recommended that riluzole should be available for the treatment of individuals with MND in accordance with its licensed indications.
Treatment with riluzole should only be started by a neurological specialist who is experienced in the management of MND. Routine supervision of therapy may be managed by general practitioners, but this should be under an agreement known as a shared care arrangement with the specialist.
- TA20 Motor neurone disease - riluzole: guidance (web format)
- TA20 Motor neurone disease - riluzole: guidance (html)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: motor neurone disease
- Motor neurone disease - riluzole: Static List Review Decision - April 2014
- Riluzole for Motor Neurone Disease - HTA report part 1
- Riluzole for Motor Neurone Disease - HTA report part 2
- Riluzole - Appeal against guidance dated December 2000
- Review of TA20 Riluzole for the treatment of motor neurone disease
- Review proposal
- Review decision
This page was last updated: 07 April 2014
- Web format
- Full Guidance (PDF)
- TA20 Arweiniad ar ddefnyddio riluzole (Rilutek) ar gyfer Trin Clefyd Niwronau Motor: deall canllawiau NICE
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.